Literature DB >> 11813242

Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice.

G A MacGibbon1, L C Hamilton, S F Crocker, W J Costain, K M Murphy, H A Robertson, E M Denovan-Wright.   

Abstract

Striatal neurons in symptomatic Huntington's disease (HD) transgenic mice are resistant to a variety of toxic insults, including quinolinic acid (QA), kainic acid and 3-nitropropionic acid. The basis for this resistance is currently unknown. To investigate the possibility that the immediate-early gene (IEG) response is defective in symptomatic HD mice leading to a lack of response to these compounds, we examined the expression of c-Fos and Krox 24 after administration of the indirect dopamine agonist methamphetamine, the dopamine D(2) receptor antagonist haloperidol and the neurotoxin QA in 5- and 10-week-old R6/2 transgenic HD and wild-type mice. Unlike wild-type and pre-symptomatic R6/2 transgenic HD mice, 10-week-old symptomatic HD mice were resistant to methamphetamine-induced gliosis and QA lesion. There was, however, no difference in the number or distribution of c-Fos-immunoreactive nuclei 2 hr after single injections of methamphetamine or haloperidol among 5- and 10-week-old wild-type mice and 5- and 10-week-old R6/2 HD mice. Similarly, despite their resistance to QA-induced lesioning and lower basal levels of krox-24 mRNA, the symptomatic R6/2 mice had equivalent increases in the amount of c-fos and krox-24 mRNA compared to wild-type and pre-symptomatic R6/2 HD mice as determined by in situ hybridization and densitometry 2 hr after QA administration. These data demonstrate that the c-Fos and Krox 24 IEG response to dopamine agonists, dopamine antagonists and neurotoxic insult is functional in symptomatic R6/2 HD mice. Resistance to toxic insult in R6/2 mice may be conferred by interactions of mutant huntingtin with proteins or transcriptional processes further along the toxic cascade. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11813242     DOI: 10.1002/jnr.10100

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  7 in total

1.  Glycolysis inhibition decreases the levels of glutamate transporters and enhances glutamate neurotoxicity in the R6/2 Huntington's disease mice.

Authors:  Ana María Estrada-Sánchez; Teresa Montiel; Lourdes Massieu
Journal:  Neurochem Res       Date:  2010-04-18       Impact factor: 3.996

Review 2.  The corticostriatal pathway in Huntington's disease.

Authors:  Carlos Cepeda; Nanping Wu; Véronique M André; Damian M Cummings; Michael S Levine
Journal:  Prog Neurobiol       Date:  2006-12-13       Impact factor: 11.685

3.  Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo.

Authors:  Eileen M Denovan-Wright; Edgardo Rodriguez-Lebron; Alfred S Lewin; Ronald J Mandel
Journal:  Neurobiol Dis       Date:  2007-11-12       Impact factor: 5.996

4.  Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease.

Authors:  Rona K Graham; Mahmoud A Pouladi; Prasad Joshi; Ge Lu; Yu Deng; Nan-Ping Wu; Bryan E Figueroa; Martina Metzler; Véronique M André; Elizabeth J Slow; Lynn Raymond; Robert Friedlander; Michael S Levine; Blair R Leavitt; Michael R Hayden
Journal:  J Neurosci       Date:  2009-02-18       Impact factor: 6.167

5.  Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.

Authors:  Hua Zhang; Qin Li; Rona K Graham; Elizabeth Slow; Michael R Hayden; Ilya Bezprozvanny
Journal:  Neurobiol Dis       Date:  2008-04-16       Impact factor: 5.996

6.  Forebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function.

Authors:  Soong Ho Kim; Carlos A Thomas; Véronique M André; Damian M Cummings; Carlos Cepeda; Michael S Levine; Michelle E Ehrlich
Journal:  ASN Neuro       Date:  2011-06-07       Impact factor: 4.146

7.  Antagonistic pleiotropy in mice carrying a CAG repeat expansion in the range causing Huntington's disease.

Authors:  A J Morton; E A Skillings; N I Wood; Z Zheng
Journal:  Sci Rep       Date:  2019-01-10       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.